Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Two anti-CD19 chimeric antigen receptor (CAR) T-cell therapies are approved for adults with relapsed or refractory large B-cell lymphoma after more than two lines of therapy. Although CAR T-cell therapy has demonstrated significant efficacy for some patients, the treatment process can be long and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaupierre, Alix, Kahle, Nicole, Lundberg, Rachel, Patterson, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521122/
https://www.ncbi.nlm.nih.gov/pubmed/33520344
http://dx.doi.org/10.6004/jadpro.2019.10.4.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521122/
https://www.ncbi.nlm.nih.gov/pubmed/33520344
http://dx.doi.org/10.6004/jadpro.2019.10.4.12

Ejemplares similares